IDEXX to Add Canine Mast Cell Tumor Detection Mid-2026 and Launch FNA Cytology
IDEXX will add canine mast cell tumor detection to its Cancer Dx Panel at no extra cost starting mid-2026 and roll out inVue Dx FNA cytology in late Q4 2025. These diagnostics will enable detection of over one-third of canine cancers with 2–4 day turnaround at 5,500+ North American practices.
1. Expansion of IDEXX Cancer Dx Panel to Include Mast Cell Tumor Detection
IDEXX Laboratories will expand its Cancer Dx Panel to incorporate canine mast cell tumor detection at no additional cost, beginning mid-2026 in North America. This enhancement builds on the existing lymphoma test—currently used by more than 5,500 North American veterinary practices—that identifies lymphoma up to eight months before clinical signs. With mast cell tumors and lymphoma combined, the panel will address over one-third of all canine cancers. Test results will be delivered within 2–3 days in the U.S. and 2–4 days in Canada, using the same blood specimen and workflow, enabling veterinarians to screen at-risk dogs (all dogs ≥ 7 years old and high-risk breeds ≥ 4 years old) during routine wellness visits and rapidly confirm suspicions in symptomatic patients.
2. Rollout of IDEXX inVue Dx FNA Cytology for In-Clinic Rapid Diagnosis
In late Q4 2025 IDEXX introduced fine-needle aspirate cytology on its inVue Dx Cellular Analyzer, offering a slide-free, in-clinic diagnostic solution for mast cell tumors in dogs. This application allows practitioners to evaluate skin masses, count and classify cells, and deliver results to pet owners during the same visit. An optional remote review by an IDEXX veterinary pathologist can be requested without additional sample preparation. The controlled U.S. rollout will expand broadly throughout 2026, with plans to add further tumor types and other cytology applications over time.
3. Market Opportunity and Strategic Outlook for Investors
Mast cell tumors are among the most common canine cancers, often misidentified without cellular analysis and undetectable via routine bloodwork. By extending its panel to mast cell tumors and deploying in-clinic cytology, IDEXX positions itself at the forefront of proactive veterinary oncology diagnostics. These innovations reinforce IDEXX’s recurring-revenue models—laboratory testing volume and analyzer consumables—and capitalize on a reference-lab network serving over 175 countries. With approximately 11,000 employees and membership in the S&P 500, IDEXX expects these offerings to drive mid-term revenue growth through increased test adoption, higher analyzer attach rates, and deeper penetration of the estimated 30,000 veterinary practices across North America.